Can You Switch from Jardiance to Farxiga After Intolerance?
Yes, switching from Jardiance (empagliflozin) to Farxiga (dapagliflozin) is reasonable and commonly done in clinical practice, but success depends entirely on the specific adverse effect that caused intolerance to Jardiance.
Understanding SGLT2 Inhibitor Class Effects vs. Individual Drug Differences
Both empagliflozin and dapagliflozin are SGLT2 inhibitors with similar mechanisms of action and share most adverse effects as class effects 1. This means many side effects will occur with both medications. However, individual patient responses can vary, making a trial of the alternative agent worthwhile in many situations.
Decision Algorithm Based on Type of Intolerance
When Switching is LIKELY to Fail (Class Effects)
If your patient experienced any of these adverse effects with Jardiance, they will likely experience them with Farxiga as well:
- Genital mycotic infections - Both drugs increase risk equally 1, 2
- Urinary tract infections - Class effect, though some data suggest slightly lower rates with empagliflozin (2.34% vs 7.08%) 2
- Volume depletion/hypotension - Both cause intravascular volume depletion 1
- Diabetic ketoacidosis - Rare but serious class effect 1
- Fournier's gangrene - Rare but occurs with all SGLT2 inhibitors 1
- Polyuria/osmotic diuresis - Inherent to the mechanism of action
For these class effects, switching to Farxiga will not solve the problem. Consider alternative drug classes (GLP-1 receptor agonists offer similar cardiovascular benefits) 3, 4.
When Switching MAY Succeed (Idiosyncratic Reactions)
If your patient experienced these issues, a trial of Farxiga is reasonable:
- Hypersensitivity reactions (angioedema, rash) - These are drug-specific, not class effects 1
- Gastrointestinal intolerance - Individual variation exists
- Subjective side effects (fatigue, malaise) - May differ between agents
When Switching is Worth Trying (Efficacy Differences)
Recent comparative data shows empagliflozin may have slightly superior glycemic efficacy compared to dapagliflozin 2, 5. If the issue was inadequate efficacy rather than true intolerance, this argues against switching. However, both drugs demonstrate:
- Similar cardiovascular mortality reduction 3, 4
- Similar heart failure hospitalization reduction 3, 4
- Similar renal protection 3
Practical Implementation
Starting Farxiga after Jardiance intolerance:
- Verify the specific adverse effect that caused discontinuation
- Correct any volume depletion before initiating Farxiga 4
- Start at 10 mg once daily (the dose tested in cardiovascular outcomes trials) 4
- Monitor closely for recurrence of the original adverse effect in the first 2-4 weeks
- Assess renal function - both drugs contraindicated if eGFR <30 mL/min/1.73 m² or on dialysis 4, 1
Critical Caveats
Do not switch if:
- Patient is on dialysis (absolute contraindication for both) 4, 1
- eGFR <30 mL/min/1.73 m² 4
- The adverse effect was serious (ketoacidosis, Fournier's gangrene, severe hypersensitivity)
- Patient had recurrent genital infections with Jardiance
Exercise caution in:
- Elderly patients (higher risk of volume depletion) 1
- Patients on loop diuretics 1
- Those with baseline renal impairment 1
Bottom Line
The decision hinges on identifying whether the intolerance was a class effect (switch will fail) or an idiosyncratic reaction (switch may succeed). For true hypersensitivity reactions to empagliflozin specifically, switching to dapagliflozin is appropriate. For class effects like genital infections or volume depletion, switching within the SGLT2 inhibitor class is futile—consider GLP-1 receptor agonists instead, which offer comparable cardiovascular benefits without SGLT2 inhibitor-specific adverse effects 3, 4.